Details

Autor(en) / Beteiligte

• Roozeman, Jan-Paul
• Mazzinari, Guido
• Serpa Neto, Ary
• Hollmann, Markus W.
• Paulus, Frederique
• Schultz, Marcus J.
• Pisani, Luigi
• Algera, A.G.
• Boers, L.S.
• Bos, L.D.J.
• Botta, M.
• Dongelmans, D.A.
• Hollmann, M.W.
• Horn, J.
• Paulus, F.
• Pillay, J.
• Schultz, M.J.
• Neto, A. Serpa
• Tsonas, A.M.
• Vlaar, A.P.J.
• Ahuja, S.
• van Akkeren, J.P.
• Algoe, C.K.
• van Amstel, R.B.
• Artigas, A.
• Baur, O.L.
• van de Berg, P.
• van den Berg, A.E.
• Bergmans, D.C.J.J.
• van den Bersselaar, D.I.
• Bertens, F.A.
• Bindels, A.J.G.H.
• de Boer, M.M.
• den Boer, S.
• Bogerd, M.
• Breel, J.S.
• de Bruin, H.
• de Bruin, S.
• Bruna, C.L.
• Buiteman-Kruizinga, L.A.
• Cremer, O.L.
• Determann, R.M.
• Dieperink, W.
• Franke, H.S.
• Galek-Aldridge, M.S.
• de Graaff, M.J.
• Hagens, L.A.
• Haringman, J.J.
• van der Heide, S.T.
• van der Heiden, P.L.J.
• Heijnen, N.F.L.
• Hiel, S.J.P.
• Hoeijmakers, L.L.
• Hol, L.
• Hoogendoorn, M.E.
• van der Horst, R.
• Ie, E.L.K.
• Ivanov, D.
• Juffermans, N.P.
• Kho, E.
• de Klerk, E.S.
• Gemert, A.W.M.M. Koopman-van
• Koopmans, M.
• Kucukcelebi, S.
• Kuiper, M.A.
• de Lange, D.W.
• van Mourik, N.
• Nijbroek, S.G.
• Onrust, M.
• Oostdijk, E.A.N.
• Pennartz, C.J.
• Pisani, L.
• Purmer, I.M.
• Rettig, T.C.D.
• Roozeman, J.P.
• Schuijt, M.T.U.
• Sleeswijk, M.E.
• Smit, M.R.
• Spronk, P.E.
• Stilma, W.
• Strang, A.C.
• Tuinman, P.R.
• Valk, C.M.A.
• Veen-Schra, F.L.
• Veldhuis, L.I.
• van Velzen, P.
• van der Ven, W.H.
• van Vliet, P.
• van der Voort, P.H.J.
• van Welie, L.
• Wesselink, H.J.F.T.
• van der Wier-Lubbers, H.H.
• van Wijk, B.
• Winters, T.
• Wong, W.Y.
• van Zanten, A.R.H.

Titel

Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 – Insights from the PRoVENT-COVID study

Ist Teil von

• Journal of critical care, 2022-04, Vol.68, p.31-37

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients. •SpO2/FiO2 is associated with 28-day mortality in ARDS due to COVID-19.•SpO2/FiO2 on days 2 and 3, but not on day 1, is independently associated with outcome.•SpO2/FiO2 is strongly correlated with PaO2/FiO2.